RxDoctor Payments Data

Lesley White, APRN

Nurse Practitioner · Louisville, KYNPI 1528374097

Payments from drug & device makers

$4,748in general payments, 2019–2025

Across 171 payments — averaging $27.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$1K
  • CSL Behring$670
  • AstraZeneca$663
  • Amgen$274
  • Genentech USA, Inc.$254
  • Sanofi$233
  • plus $1K from 21 others

What the payments were for

  • Consulting fees$1,05022%
  • Food & beverage$3,59076%
  • Education$1082%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,748 in reported general payments places this provider in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$12,665
Medicare patients
105
Services billed
551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$50,360
Spiriva RespimatTiotropium Bromide41$30,123
SymbicortBudesonide/Formoterol Fumarate36$15,687
Epinephrine55$13,666
DuleraMometasone/Formoterol18$6,375
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate26$6,349
Fluticasone-SalmeterolFluticasone Propion/Salmeterol36$4,752
Arnuity ElliptaFluticasone Furoate16$4,656
Montelukast Sodium522$3,912
Azelastine Hcl142$3,319
Fluticasone Propionate196$2,830
Levocetirizine Dihydrochloride45$1,989
Albuterol Sulfate HfaAlbuterol Sulfate60$1,974
Wixela InhubFluticasone Propion/Salmeterol11$1,214
BreynaBudesonide/Formoterol Fumarate14$1,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Arnuity Ellipta$180$55,01766 claims
Boehringer IngelheimSpiriva Respimat$76$30,12341 claims
AstraZenecaSymbicort$663$15,68736 claims
Hikma Pharmaceuticals USAEpinephrine$30$13,66655 claims
MerckDulera$16$6,37518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →